ALBIREO PHARMA INC (ALBO) Stock Price, Forecast & Analysis
USA - NASDAQ:ALBO - US01345P1066 - Common Stock
ALBO Key Statistics, Chart & Performance
The current stock price of ALBO is 44.15 USD. In the past month the price decreased by -1.23%. In the past year, price increased by 66.73%.
ALBO Latest News, Press Relases and Analysis
ALBO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About ALBO
Company Profile
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
Company Info
ALBIREO PHARMA INC
10 Post Office Square, Suite 502 South
Boston MASSACHUSETTS 02109 US
CEO: Ronald H.W. Cooper
Employees: 130
Phone: 18574154774.0
ALBIREO PHARMA INC / ALBO FAQ
What does ALBIREO PHARMA INC do?
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
What is the current price of ALBO stock?
The current stock price of ALBO is 44.15 USD. The price decreased by -0.23% in the last trading session.
Does ALBO stock pay dividends?
ALBO does not pay a dividend.
How is the ChartMill rating for ALBIREO PHARMA INC?
ALBO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for ALBO stock?
The Revenue of ALBIREO PHARMA INC (ALBO) is expected to grow by 69.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for ALBIREO PHARMA INC?
ALBIREO PHARMA INC (ALBO) currently has 130 employees.
What is the ownership structure of ALBIREO PHARMA INC (ALBO)?
You can find the ownership structure of ALBIREO PHARMA INC (ALBO) on the Ownership tab.
ALBO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALBO. When comparing the yearly performance of all stocks, ALBO is one of the better performing stocks in the market, outperforming 98.27% of all stocks.
ALBO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALBO. The financial health of ALBO is average, but there are quite some concerns on its profitability.
ALBO Financial Highlights
Over the last trailing twelve months ALBO reported a non-GAAP Earnings per Share(EPS) of -6.72. The EPS increased by 10.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALBO Forecast & Estimates
13 analysts have analysed ALBO and the average price target is 42.84 USD. This implies a price decrease of -2.97% is expected in the next year compared to the current price of 44.15.
For the next year, analysts expect an EPS growth of -20.91% and a revenue growth 69.42% for ALBO